PCN8 COST-EFFECTIVENESS ANALYSIS OF LHRH AGONISTS IN THE TREATMENT OF METASTATIC PROSTATE CANCER  by Iskedjian, M et al.
196 Abstracts
within and 74 (46,0%) outside of clinical trials (33 =
20,5% undeﬁned). For HD patients, mean hospital costs
and mean costs of chemotherapy during the ﬁrst 6 months
after initial diagnosis were €6.336,95 and €10.039,73
respectively, for NHL patients €9.787,15 and €6.720,93,
for CLL €1.055,31 and €749,04 respectively, and for
MM patients €9.016,12 and €4.870,57.
CONCLUSIONS: The continuation of this project will
make it possible to determine cost-of-illness and cost-
effectiveness ratios of different treatment modalities for
patients with malignant lymphomas and to develop
guidelines for clinical pathways.
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OBJECTIVE: To quantify the economic effect on 
employers when the spouse or dependent of an employee
is diagnosed with cancer.
METHODS: Costs based on claims data for ﬁve major
employers (number of employees exceeds 100,000) over
the period of 1995–1998 were analyzed from the employ-
ers’ perspectives. The employers’ burden is measured in
terms of direct health-related costs and indirect produc-
tivity costs (i.e., both lost worktime and reduced at-work
performance). Costs for employees who had a family
member with cancer were compared to costs for employ-
ees who did not. For employees who had a family member
with cancer, the relationship between the employee’s costs
and the timing of the family member’s cancer diagnosis
and treatment was examined. Regression analyses were
used to estimate the incremental costs associated with
caring for a family member before, during and after the
diagnosis of cancer.
RESULTS: Caregiving costs were most pronounced
during the 3-month period leading up to and the 3-month
period following diagnosis. Loss of productivity ac-
counted for most of the incremental costs and reached
approximately $1,500 per employee per year. Medical
and drug costs added approximately $230 per employee
per year. When a family member suffered from anemia in
addition to cancer, the costs during the anemia period
(deﬁned as four weeks preceding through four weeks 
following a claims diagnosis of anemia) were over 40
percent higher than in comparable cancer periods without
anemia.
CONCLUSIONS: The economic impact of caregiving for
a family member with cancer is signiﬁcant, and translates
into increased workplace costs. Moreover, this cost in-
crease is more pronounced when cancer-related anemia is
present. These patterns suggest that programs to prevent
or quickly treat a family member’s cancer and any related
anemia could yield indirect beneﬁts to employers by
reducing the burden on employees as caregivers.
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COLONOSCOPY
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Colorectal cancer is the third most common form of
cancer, representing an estimated 135,400 cases and
56,700 deaths in 2001. Because early detection of col-
orectal cancer can signiﬁcantly reduce 1-year and 5-year
relative survival rates, screening strategies are highly 
recommended. More research into the cost-effectiveness
of new screening technique compared to current methods
is needed.
OBJECTIVES: This analysis attempts to compare the
cost-effectiveness of conventional colonoscopy and
virtual colonoscopy (CT scan) as screening strategies for
the prevention of colorectal cancers in the general 
population.
METHODS: A literature review was conducted to obtain
all relevant costs and probabilities. A spreadsheet model
was constructed to perform the analysis using a hypo-
thetical cohort of the general population over age 50
years from the societal perspective using 2001 US dollars.
A series of one-way sensitivity analysis were performed
on all costs and probabilities obtained from published 
literature.
RESULTS: In the base-case analysis, the number of 
life-years saved per 100,000 was 4000 and 5600 for
virtual and conventional colonoscopy respectively. The
average cost per life-year saved was estimated at $48,200
for virtual colonoscopy and $52,200 for conventional
colonoscopy compared to no screening. The incremental
cost-effectiveness ratio (ICER) of conventional col-
onoscopy versus virtual colonoscopy was $62,100. The
model was most sensitive to the ranges used for the 
discount rate, sensitivity of conventional colonoscopy,
and the cost of conventional colonoscopy.
CONCLUSION: The ICER of conventional to virtual
colonoscopy is borderline unfavorable. Nevertheless,
because of the greater number of life-years saved with
conventional colonoscopy, it appears more favorable than
virtual colonoscopy. Due to the closeness in CEA results,
and the substantial changes with different parameter
assumptions, e.g. combinations of screening strategies
and differences in compliance rates, further data and
analyses are needed to derive a robust conclusion.
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OBJECTIVES: We performed a pharmacoeconomic 
evaluation of LHRH agonists (LAs) in treating metasta-
tic prostate cancer compared to standard care, as identi-
ﬁed in the literature and by clinical experts, including
estrogens (DES), orchiectomy, antiandrogens (AAs), and
combinations therapy (LAs + AAs).
METHODS: A Markov model was constructed to
perform a cost-effectiveness analysis (CEA) over 5 years,
from a Canadian provincial healthcare payer perspective.
Efﬁcacy of treatments was determined by meta-analysis
of clinical data.
RESULTS: In the base case analysis, DES was least costly
at $588, but also the least effective, with 1.11 expected
life-years (ELYs). The cost of orchiectomy was $830 with
a greater effectiveness of 1.71 ELYs, and an incremental
cost effectiveness ratio of $399/Life Year Gained (LYG)
over DES. AAs or LAs resulted in higher costs, $4,108
and $8,116 respectively, but lower effectiveness of 1.19
ELYs and 1.50 ELY respectively, thus were both 
dominated by orchiectomy. LAs + AAs was most costly
at $18,029, but with the highest effectiveness (1.89
ELYs), with an incremental cost effectiveness ratio 
of $97,301/LYG over orchiectomy. Changes in key-
parameters in sensitivity analyses did not affect the
ranking of the treatment strategies, suggesting that the
model was robust.
CONCLUSIONS: LAs were dominated by orchiectomy
in the base case analysis and most sensitivity analyses.
Combination therapy displayed incremental cost effec-
tiveness ratios over orchiectomy ranging from approxi-
mately $30,000 to $100,000 per LYG. Orchiectomy was
more effective, had fewer severe adverse reactions, and
cost slightly more than DES, the least expensive treat-
ment. However, due to potential psychological impact,
further research is warranted to examine its acceptance
by patients.
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Colorectal cancer (CRC) treatment is associated with
high costs, and hence, consideration of the cost-
effectiveness of available chemotherapeutic agents
becomes important in decision-making. Since use of a
single or few studies to guide allocative decisions may 
be misleading, critical reviews of all available data are
essential.
OBJECTIVE: To systematically review all published
pharmacoeconomic analyses of available chemotherapeu-
tic agents for the treatment of advanced CRC.
METHODS: Studies in English were identiﬁed from
Medline, CancerLit and HealthStar databases (1990–
2001) using key search terms: colorectal cancer,
chemotherapy, economics, and cost-effectiveness. Infor-
mation was abstracted from each study using an adapta-
tion of the cost-effectiveness analysis-reporting checklist
published by the Panel on Cost-Effectiveness in Health
and Medicine.
RESULTS: Of the 23 identiﬁed studies, only nine studies
were pharmacoeconomic analyses of chemotherapeutic
agents (5-ﬂuorouracil(FU)+levamisole/leucovorin,
irinotecan, raltitrexed). Of these nine, one failed to report
study perspective, two did not report the year of costs
while three failed to conduct sensitivity analyses. Most
studies used a payer perspective to model costs and sur-
vival was the most common end-point. Cost-effectiveness
estimates for adjuvant chemotherapy with 5-FU plus 
levamisole have been reported to be below $5,000/life-
year gained (LYG). The only study that adjusted for the
quality of survival resulted in a substantial decrease in
cost-effectiveness of chemotherapy using 5-FU and 
levamisole(Austr$2,916/LYG to $17,500/QALY). How-
ever, utilities were obtained from a small sample of
patients in this study. Estimates for irinotecan ranged
from cost savings to $10,137/LYG while raltitrexed has
been found to cost US$ 3,936 per additional patient
without severe adverse events when compared to 5-FU
regimens.
CONCLUSION: Pharmacoeconomic proﬁles of relatively
newer drugs such as irinotecan and raltitrexed look
promising but further research on their relative cost-
effectiveness is warranted to aid decision-makers. Future
cost-effectiveness research in advanced CRC patients
needs to incorporate the quality of the extended survival.
Stricter adherence to reporting guidelines for pharma-
coeconomic studies is also required.
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